Sunshine Biopharma

SBFM

시가총액 US$86만

$6.0 million upfront with an additional $14.4 million of potential aggregate gross proceeds upon the exercise of warrants FORT LAUDERDALE, FL / ACCESS Newswire / October 9, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company specializing in generic and specialty prescription medications, including drugs in the areas of oncology and antivirals, today announced the closing of its previously announced public offering made on a reasonable best efforts basis with gross proceeds to the Company of approximately $6.0 million, before deducting placement agent fees and other offering expenses payable by the Company. The offering consisted of 10,909,082 Common Units (or Pre-Funded Units), each consisting of (i) one (1) share of Common Stock or one (1) Pre-Funded Warrant and (ii) two (2) Series D Warrants to purchase one (1) share of Common Stock per warrant at an initial exercise price of $0.66.

FORT LAUDERDALE, FL / ACCESS Newswire / October 8, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company specializing in generic and specialty prescription medications, including drugs in the areas of oncology and antivirals, today announced the pricing of a public offering made on a reasonable best efforts basis with gross proceeds to the Company expected to be approximately $6.0 million, before deducting placement agent fees and other offering expenses payable by the Company. The offering consists of 10,909,083 Common Units (or Pre-Funded Units), each consisting of (i) one (1) share of Common Stock or one (1) Pre-Funded Warrant and (ii) two (2) Series D Warrants to purchase one (1) share of Common Stock per warrant at an initial exercise price of $0.66.

Sunshine Biopharma, Inc. (SBFM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Launch introduces ondansetron 4 mg and 8 mg tablets for nausea and vomiting associated with chemotherapy, radiation therapy and surgery Global ondansetron market projected to reach $2.98 billion by 2034, up from $1.82 billion in 2025, according to DataIntelo Commercial rollout supported by Nora Pharma's established Canadian distribution network, further expanding Sunshine Biopharma's generic prescription drug portfolio FORT LAUDERDALE, FL / ACCESS Newswire / September 24, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications including drugs in the areas of oncology and antivirals, is pleased to announce that it has launched generic Ondansetron tablets of 4mg and 8mg in the Canadian market. Ondansetron is the generic equivalent of the brand name, Zofran®.

Nanomolar potency against PLpro with broad-spectrum SARS-CoV-2 variants activity Significant dose-dependent suppression of pulmonary viral replication in vivo Strong oral bioavailability and preferential lung enrichment across multiple species FORT LAUDERDALE, FL / ACCESS Newswire / September 16, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications including drugs in oncology and antivirals, is pleased to announce that it has advanced its lead Coronavirus drug candidate into IND-enabling studies. The Company had previously published laboratory results on its library of Anti-Coronavirus compounds in August 2024 (J.

FORT LAUDERDALE, FL / ACCESS Newswire / August 31, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its Atenolol tablets of 25mg, 50mg and 100mg for the Canadian market. Atenolol is the generic equivalent of the brand name, Tenormin®.

K1.1 mRNA demonstrated tumor-suppressing activity as a single agent in multiple in vivo hepatocellular carcinoma models Program targets a tumor suppressor frequently mutated in difficult-to-treat lung, pancreatic and liver cancers Next phase will combine K1.1 mRNA with a cancer vaccine in NSCLC with the goal of converting "cold" tumors into "hot" tumors FORT LAUDERDALE, FL / ACCESS Newswire / August 26, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company offering and researching life-saving medicines across multiple therapeutic areas including oncology and antivirals, today provided an update and outlined next plans for its oncology project, the K1.1 mRNA lipid nanoparticle (LNP) program. The gene encoding the K1.1 mRNA is a tumor suppressor that is frequently mutated in a variety of cancers, including hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), and pancreatic cancer.

Global anti-hypertensive drug market projected to reach $37.24 billion by 2034 Enalapril is a widely prescribed ACE inhibitor used to treat hypertension, heart failure and left ventricular dysfunction Sunshine Biopharma expects Enalapril tablets in four dosage strengths to begin shipping to Canadian pharmacies by year-end 2026 FORT LAUDERDALE, FL / ACCESS Newswire / August 19, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its generic Enalapril tablets 2.5mg, 5mg, 10mg and 20mg for the Canadian market. Enalapril is the generic equivalent of the brand name, Vasotec®.

Sunshine Biopharma's Amoxicillin now shipping to Canadian pharmacies in multiple dosages and strengths Launch expands Sunshine Biopharma's growing portfolio of essential prescription medications Global Amoxicillin market projected to reach approximately $6.4 billion by 2031 FORT LAUDERDALE, FL / ACCESS Newswire / August 7, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the launch of its generic Amoxicillin formulation in the Canadian market. This strategic expansion reinforces Sunshine Biopharma's commitment to providing affordable, high-quality antibiotics to patients across Canada.

Dienogest is first-line therapy for pelvic pain associate with endometriosis The endometriosis treatment market is projected to reach $5.2 billion by 2034 FORT LAUDERDALE, FL / ACCESS Newswire / August 4, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its generic Dienogest tablets of 2mg for the Canadian market. Dienogest is the generic equivalent of the brand name, Visanne®.